AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$RGNX

Ciongoli Gregory Austin purchased $949K of RGNX

Ciongoli Gregory Austin purchased 102,603 shares of REGENXBIO Inc. (RGNX) at an average of $9.25 ($9.14–$9.36, $0.95M total) across 2 trades over 2026-08-26 to 2026-08-27.

Original reporting
SEC EDGAR · Ciongoli Gregory Austin
Published Aug 27, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RGNX
Bullish
medium confidence
Mentioned
$RGNX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGNXBullishLow
01

Why it matters

The director's purchase modestly raises confidence but is unlikely to move the stock significantly.

02

Market read

New insider purchase provides fresh data point for traders monitoring Regenxbio.

03

What to watch

No disclosed 10b5-1 plan; purchase could be opportunistic rather than strategic.

Relevance 6/10Novelty 4/10Timing: 2026-08-27 filing

Background

Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$RGNXBullishMedium confidence
Context

Director Ciongoli Gregory Austin bought 102,603 shares for $949K, increasing his stake to 118,035 shares.

Expected impact

Potential modest price uptick as market absorbs insider buying.

Evidence & confidence

Purchase size is modest relative to market cap, but director involvement adds credibility.

Market effects

Sector

Minimal impact on biotech sector; typical insider activity.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider purchase may be routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Company
    Regenxbio Inc.

    Biotech firm developing gene therapy products.

  • Insider
    Ciongoli Gregory Austin

    Director of Regenxbio.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RGNX insider trading history →

Related articles

SEP 25
$RGNXMedAI 8/10

Why is Regenxbio stock climbing today?

Regenxbio (RGNX) stock rose 3.5% in pre-market trading after presenting positive three-year data from its Phase II ALTITUDE study. 60% of participants showed clinically meaningful improvement, with no adverse events. Stifel maintained a Buy rating with a $42 price target. The broader market was modestly positive, but Regenxbio's pipeline developments drove the move.

investing.com2 min
SEP 25
$AKAMMed

Nasdaq, S&P 500 Futures Rise Despite Surging Treasury Yields: AMD, TSLA, SPCX, AKAM, BE Stocks In Focus

Nasdaq and S&P 500 futures rose despite surging Treasury yields. Akamai (AKAM) surged 20% after a $11.6B deal with Anthropic. Tesla (TSLA) trended upward following a next-gen Roadster unveil and Semi truck production news. SpaceX (SPCX) gained on AI model predictions. Bloom Energy (BE) rose 1% after reaffirming Oracle's (ORCL) fuel-cell contract. Comcast (CMCSA) fell on analyst downgrades. Regenxbio (RGNX) rose 2% on positive gene therapy data.

finance.yahoo.com3 min
SEP 25
$RGNXMedAI 8/10

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO (Nasdaq: RGNX) presented positive three-year data from its Phase II ALTITUDE study of surabgene lomparvovec for diabetic retinopathy at the Retina Society Annual Meeting. The data showed durable efficacy with 60% of participants achieving a >2-step improvement on the DRSS. No new safety signals were observed. The company is advancing the treatment in a Phase IIb/III trial.

prnewswire.com2 min